Overview

Helicobacter Pylori Eradication According to DPO-PCR Methods

Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government. However, studies of antibiotic resistance has shown that regional resistance pattern to antibiotics such as clarithromycin is increasing. Recent studies show that examining genotype resistance is effective in eradication. Currently dual priming oligonucleotide-polymerase chain reaction (DPO-PCR) is used to measure clarithromycin resistance. There has been no study of comparing the duration of eradication regimens according to DPO-PCR results. The aim of this study is to compare the eradication rate of 7- day triple therapy with 14-day triple therapy in clarithromycin susceptible strains from DPO-PCR. The investigators also aimed to compare the eradication rates of 7-day bismuth quadruple therapy with 14-day bismuth quadruple therapy from clarithromycin resistant strains from DPO-PCR.
Phase:
Phase 4
Details
Lead Sponsor:
Incheon St.Mary's Hospital
Treatments:
Bismuth
Clarithromycin